+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 233 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the pharmacokinetics, safety, and immune response of two drugs, RPH-030 and Vectibix4, in patients with metastatic colorectal cancer mCRC who have wild-type RAS genes. The study aims to show that these treatments are equivalent in how the body processes them and to compare their safety and immune effects. Additionally, the study will explore how effective these drugs are when used as first-line therapy combined with FOLFIRI chemotherapy. Participants will receive either RPH-030 or Vectibix4 intravenously at 6 mgkg every two weeks along with FOLFIRI chemotherapy, which includes irinotecan, calcium folinate, and fluorouracil. Treatment starts with FOLFIRI for 8 cycles, then continues with a modified de Gramont regimen. The study includes several periods a screening phase, a main period lasting up to 6 months, a continued therapy period up to 1 year where all patients receive RPH-030, and a treatment extension period lasting up to 2 years for patients with stable disease or response. Follow-up visits occur after treatment ends to monitor survival and disease status. Participants will undergo regular tumor assessments approximately every 6 to 8 weeks, hospitalizations for drug administration at specific visits, and blood sampling for pharmacokinetic and safety evaluations. Researchers will monitor drug levels over time, adverse events, immune reactions, and tumor responses. Follow-up includes imaging or phone calls to track overall survival and disease progression. The total study participation can last up to about 2 years with additional follow-up to ensure thorough monitoring of outcomes and safety.

Age: 18Years +All GendersPhase 1
26 locations
E

Actively Recruiting

Researchers are evaluating the safety, pharmacokinetics, pharmacodynamics, and early effects of the drug combination ZE50-0134 and Azacitidine in patients with relapsed or refractory Acute Myeloid Leukemia AML. This open-label Phase 1b study focuses on patients who have not responded to previous treatments or whose disease has returned. The study aims to find the best dose and schedule of this combination therapy using a 3 3 dose escalation design before expanding to a larger group of patients. The study has two parts first, a dose escalation phase where different doses of Lonitoclax ZE50-0134 combined with Azacitidine are tested to find the biologically effective dose. Then, an expansion phase will enroll about 30 patients divided into two groups receiving different dose levels to determine the recommended phase 2 dose. Treatments include oral capsules of ZE50-0134 given once or twice daily and Azacitidine administered at 75 mgm2 daily for 7 days. Adjustments to doses may occur based on tolerability and safety findings. Participants will be involved in up to 24 cycles of treatment, each lasting 4 weeks. They will undergo assessments including safety monitoring and measuring responses to treatment. Researchers will evaluate how well patients blood counts recover, monitor side effects, and track event-free survival and remission duration. Close monitoring during treatment helps understand the best dosing and safety profile of the combination. The total study duration may extend up to nearly two years, including follow-up periods.

Age: 18Years +All GendersPhase 1
6 locations
S

Actively Recruiting

Researchers are evaluating the safety and preliminary efficacy of OM-RCA-01, a monoclonal antibody targeting fibroblast growth factor receptor 1 FGFR1, in patients with metastatic solid tumors that express FGFR1. This Phase 1b2, multicenter, open-label study uses a basket trial design enrolling patients regardless of tumor type, focusing on cancers such as renal cell carcinoma, non-small cell lung cancer, head and neck cancer, breast cancer, and prostate cancer. The study aims to understand the medical issues participants may experience, determine appropriate dosing for future studies, and assess whether tumor growth slows with treatment. All participants will receive OM-RCA-01 through an intravenous infusion every two weeks. Treatment will continue as long as the disease remains controlled and the drug is well tolerated. The study includes five tumor-specific groups and plans to enroll 58 patients. The drug is given at dose levels of 50 mg or 100 mg, and therapy will proceed until disease progression or unacceptable toxicity occurs. Participants will be monitored through regular assessments including imaging to measure tumor lesions, laboratory tests for organ function, and questionnaires to evaluate quality of life. Safety will be closely observed by tracking adverse events, serious side effects, and the presence of anti-drug antibodies. The study will follow patients for up to 12 months to evaluate outcomes such as progression-free survival, overall survival, and duration of response.

Age: 18Years +All GendersPhase 1Phase 2
5 locations
P

Actively Recruiting

Researchers are conducting a multinational, multicenter, open-label Phase III study to evaluate the efficacy and safety of Radotinib in adults with chronic phase Philadelphia chromosome-positive chronic myeloid leukemia CP-CML who have experienced failure or intolerance to prior tyrosine kinase inhibitor TKI therapies, including Imatinib. This study aims to understand how Radotinib performs in this patient population where previous treatments have not been successful or tolerated. Participants will receive Radotinib 400 mg orally twice daily for 12 months. Dose adjustments to 600 mg or 400 mg twice daily are permitted if participants experience hematologic or non-hematologic toxicities that resolve within specified time frames. This is a single-arm study with no placebo or comparator group, involving continuous administration of the study drug throughout the treatment period. During the study, participants will be regularly monitored for responses such as major cytogenetic response at 6 months and other outcomes including complete cytogenetic response, major molecular response, overall survival, and progression-free survival up to 24 months. Safety and tolerability will also be assessed. The study enrollment started in 2018 and is expected to complete by mid-2028, with ongoing follow-up to assess long-term outcomes.

Age: 18Years +All GendersPhase 3
18 locations
G

Actively Recruiting

Researchers are evaluating the combination of APG-2575 Lisaftoclax and azacitidine compared to placebo combined with azacitidine in patients newly diagnosed with acute myeloid leukemia AML who cannot receive standard chemotherapy. This phase III, global, randomized, double-blind, placebo-controlled study aims to determine the effectiveness of this treatment approach in elderly or unfit AML patients. The study is sponsored by Ascentage Pharma Group Inc. and focuses on improving outcomes in this challenging population. Participants will be randomly assigned to receive either the investigational treatment of oral APG-2575 daily plus azacitidine injections or a placebo with azacitidine. Azacitidine is given by subcutaneous or intravenous injection on days 1 to 7 of each 28-day cycle, while APG-2575 or placebo is taken orally every day during each cycle. The treatment continues across multiple cycles with monitoring for up to five years, including evaluation of overall survival and response rates. During the study, participants will undergo regular assessments including safety evaluations, laboratory tests, and follow-up examinations to monitor treatment effects and adverse events. The primary outcome measured is overall survival over up to five years. Secondary outcomes include response rates and safety based on adverse event reports. Participants must be able to take oral medication, consent to the study, and complete all required procedures throughout the study period, which extends until 2029.

Age: 18Years +All GendersPhase 3
6 locations
O

Actively Recruiting

Researchers are evaluating the drug sarilumab in children and adolescents aged 1 to 17 years with Systemic Juvenile Idiopathic Arthritis sJIA. The study aims to describe how sarilumab behaves in the body pharmacokinetics, its effects pharmacodynamics, efficacy, and long-term safety in this population to determine an appropriate dose and treatment regimen. This is a Phase 2 open-label trial sponsored by Sanofi. Participants will receive one of two ascending doses or an additional intermediate dose of sarilumab by subcutaneous injection based on body weight. The selected dose will be administered once identified. Treatment begins with a 12-week core phase followed by a 144-week extension phase during which sarilumab continues to be given. After treatment, there is a 6-week post-treatment follow-up. Throughout the 166-week total study duration, participants will be monitored with various assessments including blood tests to measure drug levels and disease activity, evaluations of adverse events, and questionnaires to assess well-being and symptoms. Measurements like juvenile arthritis response rates and disease activity scores are tracked during both the core and extension phases. Safety, including injection site reactions and changes in glucocorticoid use, is also followed closely.

Age: 1Year - 17YearsAll GendersPhase 2
40 locations
E

Actively Recruiting

This research aims to provide continued treatment to participants with cancer who are still receiving study therapy in a Genentech or F. Hoffmann-La Roche sponsored trial and who lack local access to these treatments. It involves an open-label, multicenter extension phase where eligible patients can continue on investigational therapies following their original study. Participants will continue receiving Roche investigational medicinal products IMPs either as monotherapy or combined with other agents, following the dosing, schedule, and administration used in their parent study. Treatment can continue until disease progression, loss of clinical benefit, unacceptable toxicity, pregnancy, non-compliance, local treatment availability, withdrawal, or study termination by the sponsor. Throughout the study, participants will be monitored for ongoing access to the study drugs and for adverse events using standardized criteria over approximately 10 years. Safety and clinical benefit assessments will guide continuation. The study offers long-term observation to evaluate treatment continuation and tolerability, with participation lasting until one of the stopping criteria is met or up to the study end date.

All AgesAll GendersPhase 3
77 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Age: 18Years +All GendersPhase 3
28 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug ozanimod RPC1063 in treating pediatric participants aged 2 to 17 years who have moderate to severe active ulcerative colitis UC. These participants have not responded adequately to standard treatments. The study is a combined Phase 23, randomized, double-blind trial aimed at achieving and maintaining clinical remission in this population. Participants will receive oral ozanimod at different dose levels as part of the study. The treatment involves specified doses given on specific days. The study includes two experimental groups receiving either a high or low dose of ozanimod. The trial will assess outcomes over various time points, including up to 70 weeks for pharmacokinetics and safety monitoring, and follow-up for adverse events up to 6 years. During the study, participants will be closely monitored through clinical assessments, endoscopic evaluations, and laboratory tests. Researchers will measure remission rates, clinical responses, symptomatic remission, corticosteroid-free remission, endoscopic improvement, and lymphocyte counts. Safety will be tracked by documenting adverse events and serious adverse events throughout the study and follow-up period. The primary outcome is the proportion of participants achieving clinical remission at Week 52.

Age: 2Years - 17YearsAll GendersPhase 2Phase 3
91 locations
L

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the drug baricitinib for treating Juvenile Idiopathic Arthritis JIA in children and adolescents aged 1 to less than 18 years. This Phase 3 study focuses on participants who have already taken part in previous baricitinib studies for JIA to understand long-term effects. Participants receive baricitinib orally as the study treatment. This is a single-group study, meaning all participants will take baricitinib without comparison to a placebo or other drugs. The study follows participants for up to 264 weeks about 5 years to monitor treatment effects and safety over a long period. During the study, researchers will track serious adverse events, any permanent stops of baricitinib, and various measures of disease activity, pain, and skin condition related to JIA. These include assessments like the Pediatric American College of Rheumatology response index and Juvenile Arthritis Disease Activity Score. Participants will be monitored regularly throughout the study to evaluate health and immune responses while taking the study drug.

Age: 1Year - 18YearsAll GendersPhase 3
77 locations

1-10 of 233

1